Literature DB >> 26722295

MicroRNA-34c targets TGFB-induced factor homeobox 2, represses cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma.

Yan Wang1, Chun-Mei Wang2, Zhen-Zhong Jiang3, Xiao-Jian Yu1, Chun-Guang Fan4, Fei-Fei Xu1, Qing Zhang5, L I Li1, Rui-Feng Li1, Wen-Sheng Sun6, Zhen-Hai Zhang7, Yu-Gang Liu1.   

Abstract

MicroRNAs (miRs) are short, non-coding RNAs with post-transcriptional regulatory functions. Previous studies have demonstrated that miR-34c is involved in diverse biological processes, including carcinogenesis. The aim of the present study was to investigate the role of miR-34c and its target genes in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Expression levels of miR-34c and its predicted target genes were measured. The target genes were validated by a luciferase assay. The effects of miR-34c restoration were evaluated by the detection of HBV antigens, cell proliferation and apoptosis in vitro, in addition to the tumor growth in vivo. The data demonstrated that miR-34c was downregulated in HBV-associated HCC clinical tissues and HCC cell lines compared with their corresponding controls. transforming growth factor-β-induced factor homeobox 2 (TGIF2), a transcription factor repressing transforming growth factor-β (TGFβ) signaling, was observed to be upregulated and was identified as a target gene of miR-34c. The restoration of miR-34c in HepG2.2.15 cells suppressed TGIF2 expression, HBV replication and viral antigen synthesis; inhibited cell proliferation; and induced apoptosis. miR-34c also inhibited tumor growth in a mouse model. The present study indicates that miR-34c may act as a tumor suppressor by targeting TGIF2 during HBV-associated hepatocellular carcinogenesis. miR-34c and TGIF2 may represent key regulatory factors, diagnostic markers and therapeutic targets for the prevention and treatment of HBV-associated HCC.

Entities:  

Keywords:  TGFB-induced factor homeobox 2; hepatitis B virus; hepatocellular carcinoma; microRNA; microRNA-34c

Year:  2015        PMID: 26722295      PMCID: PMC4665706          DOI: 10.3892/ol.2015.3649

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  37 in total

1.  A Smad transcriptional corepressor.

Authors:  D Wotton; R S Lo; S Lee; J Massagué
Journal:  Cell       Date:  1999-04-02       Impact factor: 41.582

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells.

Authors:  Fengyan Yu; Yu Jiao; Yinghua Zhu; Ying Wang; Jingde Zhu; Xiuying Cui; Yujie Liu; Yinghua He; Eun-Young Park; Hongyu Zhang; Xiaobin Lv; Kelong Ma; Fengxi Su; Jong Hoon Park; Erwei Song
Journal:  J Biol Chem       Date:  2011-11-10       Impact factor: 5.157

4.  Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210.

Authors:  Guang-ling Zhang; Yi-xuan Li; Shu-qi Zheng; Min Liu; Xin Li; Hua Tang
Journal:  Antiviral Res       Date:  2010-08-20       Impact factor: 5.970

5.  Epidermal growth factor signaling via Ras controls the Smad transcriptional co-repressor TGIF.

Authors:  R S Lo; D Wotton; J Massagué
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

6.  Diagnosis of hepatocellular carcinoma nodules in patients with chronic liver disease using contrast-enhanced sonography: usefulness of the combination of arterial- and kupffer-phase enhancement patterns.

Authors:  Kunio Suzuki; Yorihide Okuda; Makiyo Ota; Fumiyoshi Kojima; Masayoshi Horimoto
Journal:  J Ultrasound Med       Date:  2015-03       Impact factor: 2.153

7.  miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV.

Authors:  Lipeng Qiu; Hongxia Fan; Wensong Jin; Bao Zhao; Yanzhong Wang; Ying Ju; Lizhao Chen; Yu Chen; Zhongping Duan; Songdong Meng
Journal:  Biochem Biophys Res Commun       Date:  2010-07-13       Impact factor: 3.575

8.  Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

Authors:  Valery Tarasov; Peter Jung; Berlinda Verdoodt; Dmitri Lodygin; Alexey Epanchintsev; Antje Menssen; Gunter Meister; Heiko Hermeking
Journal:  Cell Cycle       Date:  2007-05-11       Impact factor: 4.534

9.  Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer.

Authors:  Minoru Toyota; Hiromu Suzuki; Yasushi Sasaki; Reo Maruyama; Kohzoh Imai; Yasuhisa Shinomura; Takashi Tokino
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

10.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

View more
  14 in total

1.  MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2.

Authors:  Songyan Wu; Xiangfeng He; Miao Li; Fangfang Shi; Di Wu; Meng Pan; Mei Guo; Rong Zhang; Shouhua Luo; Ning Gu; Jun Dou
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

Review 2.  The role of microRNAs in hepatocyte metabolism and hepatitis B virus replication.

Authors:  Wanyu Deng; Mengji Lu
Journal:  Virol Sin       Date:  2016-12-28       Impact factor: 4.327

3.  MicroRNA-34a alleviates steroid-induced avascular necrosis of femoral head by targeting Tgif2 through OPG/RANK/RANKL signaling pathway.

Authors:  Wu-Xun Peng; Chuan Ye; Wen-Tao Dong; Lei-Luo Yang; Chun-Qing Wang; Ze-An Wei; Jian-Hua Wu; Qing Li; Jin Deng; Jian Zhang
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-28

4.  MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell lung cancer.

Authors:  You-Jin Lu; Rong-Yu Liu; Kun Hu; Ying Wang
Journal:  Tumour Biol       Date:  2016-07-22

5.  Expression Profiling of Cellular MicroRNA in Asymptomatic HBsAg Carriers and Chronic Hepatitis B Patients.

Authors:  Xianliang Hou; Yan Liang; Jianing Chen; Yingfeng Wei; Ping Zeng; Lin Wang; Chong Lu; Hongyan Diao
Journal:  Biomed Res Int       Date:  2017-08-23       Impact factor: 3.411

6.  MiR-129-5p inhibits glioma cell progression in vitro and in vivo by targeting TGIF2.

Authors:  Yuling Diao; Baozhe Jin; Liyong Huang; Wenke Zhou
Journal:  J Cell Mol Med       Date:  2018-02-12       Impact factor: 5.310

Review 7.  MicroRNAs-Based Nano-Strategies as New Therapeutic Approach in Multiple Myeloma to Overcome Disease Progression and Drug Resistance.

Authors:  Vanessa Desantis; Ilaria Saltarella; Aurelia Lamanuzzi; Assunta Melaccio; Antonio Giovanni Solimando; Maria Addolorata Mariggiò; Vito Racanelli; Angelo Paradiso; Angelo Vacca; Maria Antonia Frassanito
Journal:  Int J Mol Sci       Date:  2020-04-27       Impact factor: 5.923

8.  West Nile virus infection and interferon alpha treatment alter the spectrum and the levels of coding and noncoding host RNAs secreted in extracellular vesicles.

Authors:  Andrii Slonchak; Brian Clarke; Jason Mackenzie; Alberto Anastacio Amarilla; Yin Xiang Setoh; Alexander A Khromykh
Journal:  BMC Genomics       Date:  2019-06-10       Impact factor: 3.969

9.  A novel miR-0308-3p revealed by miRNA-seq of HBV-positive hepatocellular carcinoma suppresses cell proliferation and promotes G1/S arrest by targeting double CDK6/Cyclin D1 genes.

Authors:  Xiaoming Dai; Ruixue Huang; Sai Hu; Yao Zhou; Xiaoya Sun; Pucheng Gui; Zijian Yu; Pingkun Zhou
Journal:  Cell Biosci       Date:  2020-02-27       Impact factor: 7.133

10.  Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway.

Authors:  Xian Qin; Changsheng Li; Tao Guo; Jing Chen; Hai-Tao Wang; Yi-Tao Wang; Yu-Sha Xiao; Jun Li; Pengpeng Liu; Zhi-Su Liu; Quan-Yan Liu
Journal:  J Exp Clin Cancer Res       Date:  2017-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.